Physician profile
Theodore Manny
NPI 1871773143
$3,244.48
in general payments reported to CMS, 2019-2025
28 companies · $434 in 2025
The $434 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $124 · 2021: $284 · 2022: $799 · 2023: $252 · 2024: $357 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $625.46 | 2019-2024 | Xtandi, Myrbetriq |
| Pfizer INC. | $439.02 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $307.88 | 2019-2024 | |
| Janssen Biotech, INC. | $265.31 | 2025 | Carvykti, Rybrevant, Balversa |
| Myovant Sciences INC. | $209.76 | 2021-2022 | |
| Urogen Pharma, INC. | $194.19 | 2022 | |
| Dendreon Pharmaceuticals LLC | $174.52 | 2019-2025 | Provenge |
| Abbvie INC. | $130.44 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $125.88 | 2019 | |
| Foundation Medicine, INC. | $115.76 | 2022-2023 | |
| Intuitive Surgical, INC. | $114.65 | 2022 | |
| Neotract INC. | $93.51 | 2019 | |
| Amgen INC. | $60.43 | 2019-2020 | |
| Boston Scientific Corporation | $59.52 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $48.19 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioprotect Medical, INC. | $43.64 | 2025 | Bioprotect Balloon Implant System |
| Ferring Pharmaceuticals INC. | $34.66 | 2019 | |
| Travere Therapeutics, INC. | $31.60 | 2019-2022 | |
| Antares Pharma, INC. | $29.86 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $21.38 | 2023 | Orgovyx |
| Cycle Pharmaceuticals INC | $20.60 | 2025 | Venxxiva |
| Ethicon US, LLC | $20.29 | 2024 | Enseal |
| Blue Earth Diagnostics | $18.66 | 2019 | |
| Laborie Medical Technologies Corp. | $17.68 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Merck Sharp & Dohme LLC | $16.59 | 2020 | |
| Procept Biorobotics Corporation | $13.31 | 2019 | |
| Allergan, INC. | $11.69 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Manny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.